Short answer
MYRIAD GENETICS INC (MYGN) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Signature block only; no earnings results or financial metrics disclosed in the provided text.
MYRIAD GENETICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Signature block only; no earnings results or financial metrics disclosed in the provided text
- Filed May 5, 2026, and signed by CFO Benjamin R. Wheeler
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $200.4M, up 2%, with stable 385,000 tests and 2% average revenue-per-test growth
- Cancer Care Continuum revenue rose 4% to $120.2M, while Prenatal Health fell 15% to $41.9M
- GeneSight revenue increased 24% to $38.3M, supported by 7% volume growth and improved reimbursement
- GAAP net loss widened to $34.1M, or $0.36 per share; adjusted EBITDA remained negative at $(4.5)M
- 2026 guidance reaffirmed: revenue $860M-$880M, adjusted gross margin 68%-69%, adjusted EBITDA $37M-$49M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MYRIAD GENETICS INC 8-K filings
Get the next MYGN 8-K as it lands
Follow MYGN for push alerts, or ask the research agent what this filing means.